A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

We established an efficient way to deplete intestinal bacteria in three days, and subsequently transplant fecal microbiota via gavage of fecal fluid prepared from fresh or frozen intestinal contents in mice. We also present an optimized method to detect the frequency of IgA-coated bacteria in the gut.

Abstract

Gut microbiota exert pleiotropic roles in human health and disease. Fecal microbiota transplantation (FMT) is an effective method to investigate the biological function of intestinal bacteria as a whole or at the species level. Several different FMT methods have been published. Here, we present an FMT protocol that successfully depletes gut microbiota in a matter of days, followed by transplantation of fecal microbiota from fresh or frozen donor intestinal contents to conventional mice. Real time-PCR is applied to test the efficacy of bacterial depletion. Sequencing of the 16S ribosomal RNA (rRNA) is then applied to test the relative abundance and identity of gut microbiota in recipient mice. We also present a flow cytometry-based detection method of immunoglobulin A (IgA)-coated bacteria in the gut.

Introduction

A diverse gut microbiota plays a major role in maintaining host homeostasis. This microbiome aids in various physiological processes ranging from digestion and absorption of nutrients from food, defense against infection of pathogens, regulation of immune system development, and immune homeostasis1. Perturbation in gut microbial composition has been linked to many diseases, including cancer2, autoimmune diseases3, inflammatory bowel disease4, neurological diseases5, and metabolic diseases6,7. Germ-free (GF) mice are powerful tools in fecal microbiota transplantation models to study the biological effects of microbiota8. However, the GF housing environment is very stringent, and performing fecal microbiota transplantation (FMT) in these mice is expensive. Moreover, GF mice have different barrier and mucosal properties, which regulate bacterial penetration, compared to conventional mice9. These factors limit the wide application of GF mice in studies. An alternative to using GF mice is to deplete the microbiota in conventional mice using an antibiotic cocktail followed by FMT. Previously reported FMT methods are not well described and inconsistent; therefore, it is necessary to establish a feasible, efficient, and reproducible protocol to perform FMT using conventional mice.

Several steps are crucial to a successful FMT. The efficiency of microbiota depletion is the first important step. For bacteria depletion, use of a single broad-spectrum antibiotic (e.g., streptomycin10) or an antibiotic cocktail (triple or quadruple-antibiotic treatment) has been reported11,12. The quadruple-antibiotic treatment including ampicillin, metronidazole, neomycin, and vancomycin, has been found to be the most effective regimen and has been used in several studies13,14,15. In addition to the type of antibiotic used, the route of administration, dosage, and duration of the antibiotic treatment affect the efficacy of bacterial depletion. Some researchers apply antibiotics in the drinking water to eliminate bacteria in the gastrointestinal tract15. However, it is hard to control the dosage of antibiotics that each mouse receives this way. Therefore, in subsequent studies, researchers have treated mice with antibiotics by oral gavage for 1–2 weeks12 to achieve satisfactory depletion. However, the long-term use of antibiotics can be problematic, as the antibiotics themselves may affect some diseases in rodent models16. Therefore, faster and more efficient methods for microbiota depletion are warranted.

Fecal fluid preparation is another key step to ensure successful FMT. In the gastrointestinal tract, pH ranges from 1 in the stomach to 7 in the proximal and distal intestine9. The microbiota in the stomach is limited due to high acidity and includes Helicobacter pylori17. The proximal intestine produces bile acid for the liver-gut circulation, and contains microbiota associated with fat, protein, and glucose digestion. The distal intestinal tract contains abundant anaerobic bacteria and exhibits high microbial diversity18. Given the spatial heterogeneity of gut microbiota, it is imperative to isolate gut contents from different regions of the intestinal tracts for fecal fluid preparation. Additionally, other factors, including the nature of the donor sample (e.g., fresh or frozen sample), transplantation frequency, and duration are crucial when performing FMT. Frozen stool is most commonly used for colonizing conventional mice with human gut microbiota19. In contrast, FMT using fresh stool from animal donors is more appropriate and commonly used in animal models20,21. FMT frequency and duration vary depending on the experimental design and models. In previous studies, FMT was either performed daily or every second day. The transplantation duration ranged from 3 days22 to 5 weeks23. In addition to the above factors, maintaining an aseptic surgical environment and the use of sterilized surgical instruments is crucial to avoid unexpected environmental bacterial contamination.

The gut microbiota has the potential to regulate the accumulation of cells that express Immunoglobulin A (IgA). IgA, a predominant antibody isotype, is critical in protecting the host from infection through neutralization and exclusion. High-affinity IgA is transcytosed into the intestinal lumen and can bind and coat offending pathogens. In contrast, coating with IgA may provide a colonization advantage for bacteria24. In contrast to pathogen-induced IgA, indigenous commensal-induced IgA has lower affinity and specificity25. The proportion of intestinal bacteria coated with IgA is reported to be significantly increased in some diseases25,26. IgA-coated bacteria can initiate a positive feedback loop of IgA production27. Therefore, the relative level of IgA-coated bacteria can predict the magnitude of the inflammatory response in the gut. In fact, this combination can be detected via flow cytometry28. Using IgA-based sorting, Floris et al.27, Palm et al.25, and Andrew et al.29 acquired IgA+ and IgA- fecal bacteria from mice and characterized taxa-specific coated-intestinal microbiota via 16S rRNA sequencing.

In this study, we describe an optimized method to efficiently deplete intestinal dominant bacteria and colonize conventional mice with fresh or frozen fecal microbiota isolated from the contents of the ileum and colon. We also demonstrate a method based on flow cytometry to detect IgA-binding bacteria in the gut.

Protocol

Animal experiments were conducted in accordance with the current ethical regulations for animal care and use in China.

NOTE: Animals were housed in a specific pathogen-free (SPF), controlled environment under 12-hour light and dark cycles at 25 °C. Food was irradiated before being fed to mice. Drinking water and cages were autoclaved before use. Eight-week-old male C57BL/6J mice were used in the study following 1 week of acclimatization. They were divided into several groups based on the experiment design. Each group consisted of at least three mice.

1. Gut microbiota depletion

  1. Antibiotic cocktail preparation
    1. Prepare an antibiotic solution in sterile phosphate buffered saline (PBS) with 0.5 mg/mL vancomycin hydrochloride, 1 mg/mL metronidazole, 1 mg/mL ampicillin sodium salt, and 1 mg/mL neomycin sulfate.
      NOTE: Store the antibiotics at 2–8 °C and avoid direct light. Prepare the antibiotic cocktail solution fresh and use immediately.
  2. Treatment regimen
    1. For 3 days, orally administer 200 μL of prepared antibiotic cocktail with a #10 needle to a mouse. Hold the mouse vertically in one hand while using the other hand to adjust the angle of the needle to avoid reaching the stomach.
      NOTE: The mouse must be handled gently to avoid struggling, because surface damage of the esophagus and stomach may result in inflammation or death.
    2. Add antibiotics to the drinking water at the same concentrations as indicated in step 1.1.1.
    3. Three days later, sacrifice the mouse by CO2 asphyxiation.
    4. Dissect the abdomen aseptically using sterile instruments. At a distance of 2 cm away from the caecum, cut off a 2 cm tract of the ileum. Using sterile tweezers to clamp off one end of the tract, squeeze the fresh contents out of the tract into pre-weighed tubes.
    5. To collect the contents of the cecum, cut it in half with surgical scissors. Squeeze the contents of each half of the cecum into pre-weighed tubes.
  3. Evaluate gut microbiota depletion efficacy.
    1. Weigh gut contents isolated from the ileum or cecum from naive mice and antibiotic cocktail treated mice, and extract stool microbiota DNA using a kit according to the manufacturer’s instructions. Determine the DNA concentration according to the formula:

      concentrationsample (μg/mL) = OD260 x 50
       
    2. Construct a standard curve.
      1. Amplify E. Coli genes with a polymerase chain reaction (PCR) using V3-V4 specific primers. Predenature at 95 °C for 1 min, amplify for 40 cycles of 95 °C for 10 s, 60 °C for 30 s, 72 °C for 30 s.
      2. Construct a plasmid by linking the amplified product to a TA vector. Clone the culture with a TA vector kit according to the manufacturer’s instructions.
      3. Measure the plasmid concentration (ng/μL) based on the OD260 value as described in step 1.3.1.
        NOTE: The unit for plasmid concentration is different from the unit for DNA concentration.
      4. Calculate the copy numbers using the following formula, where MW stands for molecular weight:

        copies in 1 μL = concentration (ng/μL) x 10-9 x 6.02 x 1023/(MWplasmid x 660)
         
      5. Reconstitute the plasmid with double distilled water to a final concentration of 40 µg/μL. Prepare a 10x gradient dilution series with eight stages. Construct a standard curve by plotting the CT value (Y-axis) against log (Copiesplasmid) (X-axis) after PCR amplification, where CT stands for threshold cycle for target amplification. Extract the equation from the plot (in this case, it was y = -3.07x + 45.07, R2 = 0.994).
    3. Amplify 1 μL of the DNA samples obtained in step 1.3.1 extracted from the ileum or cecum from a naive control group and the antibiotic cocktail treatment group by real-time PCR as described in step 1.3.2.1. Calculate the copy number in 1 μL of the DNA samples based on the standard curve in step 1.3.2.5 and then calculate the total copy number using the following formula:
      Total copy number (per mg) in the weighted samples = copy numbers × total DNA volume/initial weight of the sample
  4. Analyze the microbiota DNA by sequencing the 16S rRNA V3 and V4 regions.

2. Fecal microbiota transplantation

  1. Fecal fluid preparation for both fresh and frozen stool samples
    NOTE: All instruments are soaked in 75% alcohol prior to usage to avoid preexisting bacterial contamination. It is crucial to avoid contamination when the ileum and colon contents are collected.
    1. Sacrifice 3–5 donor mice by CO2 asphyxiation.
    2. Collect the contents of the ileum as described in step 1.2.4.
    3. To collect the contents in the colon, make the first incision near the anus and cut the upper 2 cm tract. Extract the contents as explained in step 1.2.4. Collect the samples in 1 min to reduce exposure to air.
    4. For frozen fecal fluid, collect the ileum or colon contents as described in steps 2.1.2 and 2.1.3, and flash freeze the contents in liquid nitrogen.
    5. Store samples in a -80 °C freezer until ready for use.
  2. Pool and weigh the contents, add in fresh sterile tubes with beads. For frozen samples, thaw the fecal pellets on ice before weighing.
  3. Add sterile PBS into the tube and resuspend the fecal pellets in PBS (1 mL of PBS/0.2 g of fecal pellet) using a 5 mL syringe needle. Homogenize the fecal pellet completely with beads and vortex 3x for 1 min each.
  4. Centrifuge at 800 x g for 3 min, then filter the supernatants by passing through a 70 µm cell strainer. Collect the filtered fecal fluid in a sterile tube and use for FMT immediately.

3. Fecal microbiota transplantation procedure

  1. Administer 200 µL of prepared fecal fluid to the microbiota-depleted mice via oral gavage every second day for 7 days. Gavage control mice with 200 µL of sterile PBS.
  2. Sacrifice the mice by CO2 asphyxiation and harvest the contents from the ileum and colon according to steps 2.1.2 and 2.1.3. Store samples at -80 °C until further processing.
  3. Extract the microbiota DNA of the ileum and colon contents as described in step 1.3.1. Verify the microbiota composition in the gut of transplanted mice by 16S rRNA sequencing.

4. IgA-coated bacteria measurement

  1. Sample preparation
    1. Collect 50 mg of fecal pellets from donor mice as described in steps 2.1.2 and 2.1.3, and incubate in 1 mL of sterile PBS at 4 °C for 1 h. Homogenize the pellets using a bead beater for 5 s.
    2. Centrifuge the solution at 300 x g for 10 min at 4 °C. Collect supernatant after filtrating through a 70 µm strainer.
      NOTE: Avoid high speed centrifugation.
    3. Add 5 µL of the supernatant to 1 mL of 1% bovine serum albumin (BSA) in PBS (FACS buffer). Pellet at 8,000 x g for 5 min at 4 °C and discard the supernatant.
    4. Resuspend the pellet in 1 mL of FACS buffer, centrifuge at 8,000 x g for 5 min at 4 °C, and discard the supernatant.
      NOTE: The volume used here may need to be optimized. Too much of the supernatant at this step may mask the positive signal of IgA-coated bacteria.
    5. Resuspend the pellet in 100 µL of PBS containing 10% goat serum and incubate on ice or at 4 °C for 30 min. Add 1 mL of FACS buffer in the tube and centrifuge at 8,000 x g for 5 min at 4 °C to pellet.
  2. Flow cytometry
    1. Resuspend the pellet obtained in step 4.1.5 with 200 µL of FACS buffer containing biotin anti-mouse IgA antibody (1:100) and APC-conjugated anti-biotin antibody (1:100) and incubate for 30 min at 4 °C.
    2. Add 1 mL of FACS buffer in the tube and centrifuge at 8,000 x g for 5 min at 4 °C. Discard the supernatant.
    3. Stain the pellet from step 4.2.2 by adding 200 µL of FACS buffer containing green fluorescent nucleic acid stain (1:200) and incubate at 4 °C for 5 min.
    4. Add 1 mL of FACS buffer and centrifuge at 8,000 x g for 5 min at 4 °C to pellet.
    5. Resuspend the pellet in 250 µL of FACS buffer before measurement.
    6. Acquire the data using a flow cytometer and analyze it using FlowJo software.

Results

The FMT schedule used in this study is outlined in Figure 1. After treatment with the antibiotic cocktail, the efficiency of intestinal microbiota depletion was analyzed by sequencing the 16S rRNA region. We detected 196 species in the ileum of naive mice, whereas 3-day antibiotic treatment rapidly reduced the bacterial species to 35 (Figure 2A). There were eight species detected solely in mice that underwent the antibiotic cocktail treatment (

Discussion

Antibiotics used in the depletion procedure have different antibacterial properties. Vancomycin is specific for gram-positive bacteria30. Oral doxycycline can induce significant intestinal microbiota composition changes in female C57BL/6NCrl mice31. Neomycin is a broad-spectrum antibiotic that targets most gut-resident bacteria32. It does not prevent intestinal inflammation, however. Broad-spectrum antibiotic cocktails are more effective than a singl...

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was carried out under the sponsor of Outstanding interdisciplinary project of West China Hospital, Sichuan University (Grant Nr: ZYJC18024) and National Natural Science Foundation of China (Grant: 81770101 and 81973540).

Materials

NameCompanyCatalog NumberComments
5 mL syringe needleSheng guang biotech5mL
70 µm cell strainerBD biosciences352350
Ampicillin sodium saltAMERESCO0339
APC StreptavidinBD biosciences554067
Biotin anti-mouse IgA antibodyBiolegend407003
Bovine serum albiumin (BSA)SigmaB2064-50G
C57BL/6J miceChengdu Dashuo
CO2Xiyuan biotech
E.Coil genome DNATsingKe
Eppendorf tubesAxygenMCT150-C
Fast DNA stool mini HandbookQIAGEN51604
MetronidazoleShyuanyeS17079-5g
Neomycin sulfateSIGMAN-1876
Oral gavage needleYuke biotech10#
pClone007 Versatile simple TA vector kitTsingKe007VS
Phosphate Buffer Saline (PBS)HycloneSH30256
Precellys lysing kitPrecellysKT03961-1-001.2
RT PCR SYBR MIXVazymeQ411-01
SYTO BC green Fluorescent Nucleic Acid StainThermo fisher scientificS34855
V338 F primerTsingKeACTCCTACGGGAGGCAGCAG
V806 R primerTsingKeGGACTACHVGGGTWTCTAAT
Vancomycin hydrochlorideSigmaV2002
Equipments
BD FACSCalibur flow cytometerBD biosciences
Bead beater vortxScilogex
BIORAD CFX ConnectBIORAD
Centrifuge machineEppendorf
Illumina MiSeqIllumina
Nanodrop nucleic acid measurements machineThermo fisher scientific
Surgical instrumentsYuke biotech
Software
Adobe Illustrator CC 2015Version 2015
BIORAD CFX qPCR SOFTWARE
FlowJo software
Graphpad prism 7
Database
Silva (SSU132) 16S rRNA database

References

  1. Honda, K., Littman, D. R. The microbiota in adaptive immune homeostasis and disease. Nature. 535 (7610), 75-84 (2016).
  2. Weng, M. T., et al. Microbiota and gastrointestinal cancer. Journal of the Formosan Medical Association. 118 (1), 32-41 (2019).
  3. Lee, Y. K., Menezes, J. S., Umesaki, Y., Mazmanian, S. K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America. 108, 4615-4622 (2011).
  4. Lankelma, J. M., Nieuwdorp, M., de Vos, W. M., Wiersinga, W. J. The gut microbiota in internal medicine: implications for health and disease. Netherlands Journal of Medicine. 73 (2), 61-68 (2015).
  5. Soto, M., et al. Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism. Molecular Psychiatry. 23, 2287-2301 (2018).
  6. Turnbaugh, P. J., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 444 (7122), 1027-1031 (2006).
  7. Le Roy, T., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 62 (12), 1787-1794 (2013).
  8. Anhe, F. F., et al. Treatment with camu camu (Myrciaria dubia) prevents obesity by altering the gut microbiota and increasing energy expenditure in diet-induced obese mice. Gut. 68 (3), 453-464 (2019).
  9. Reikvam, D. H., et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS ONE. 6 (3), 17996 (2011).
  10. Bao, H. D., et al. Alterations in the diversity and composition of mice gut microbiota by lytic or temperate gut phage treatment. Applied Microbiology and Biotechnology. 102 (23), 10219-10230 (2018).
  11. Ishikawa, D., et al. The Microbial Composition of Bacteroidetes Species in Ulcerative Colitis Is Effectively Improved by Combination Therapy With Fecal Microbiota Transplantation and Antibiotics. Inflammatory Bowel Diseases. 24 (12), 2590-2598 (2018).
  12. Samuelson, D. R., et al. Alcohol-associated intestinal dysbiosis impairs pulmonary host defense against Klebsiella pneumoniae. PLoS Pathogens. 13 (6), 1006426 (2017).
  13. Cho, Y., et al. The Microbiome Regulates Pulmonary Responses to Ozone in Mice. American Journal of Respiratory Cell and Molecular Biology. 59 (3), 346-354 (2018).
  14. Kang, C., et al. Gut Microbiota Mediates the Protective Effects of Dietary Capsaicin against Chronic Low-Grade Inflammation and Associated Obesity Induced by High-Fat Diet. MBio. 8 (3), (2017).
  15. Kaliannan, K., Wang, B., Li, X. Y., Kim, K. J., Kang, J. X. A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. Scientific Reports. 5, 11276 (2015).
  16. Dapito, D. H., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 21 (4), 504-516 (2012).
  17. Hold, G. L., Hansen, R. Impact of the Gastrointestinal Microbiome in Health and Disease: Co-evolution with the Host Immune System. Current Topics in Microbiology and Immunology. 421, 303-318 (2019).
  18. Suzuki, T. A., Nachman, M. W. Spatial Heterogeneity of Gut Microbial Composition along the Gastrointestinal Tract in Natural Populations of House Mice. PLoS ONE. 11 (9), (2016).
  19. McDonald, J. A. K., et al. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota. Gastroenterology. 155 (5), 1495-1507 (2018).
  20. Ramai, D., Zakhia, K., Ofosu, A., Ofori, E., Reddy, M. Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Annals of Gastroenterology. 32 (1), 30-38 (2019).
  21. Hu, J., et al. Standardized Preparation for Fecal Microbiota Transplantation in Pigs. Frontiers in Microbiology. 9, 1328 (2018).
  22. Tian, H. L., et al. Treatment of Slow Transit Constipation With Fecal Microbiota Transplantation: A Pilot Study. Journal of Clinical Gastroenterology. 50 (10), 865-870 (2016).
  23. Wong, S. H., et al. Gavage of Fecal Samples From Patients with Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-free and Conventional Mice. Gastroenterology. 153 (6), 1621-1633 (2017).
  24. Macpherson, A. J., Yilmaz, B., Limenitakis, J. P., Ganal-Vonarburg, S. C. IgA Function in Relation to the Intestinal Microbiota. Annual Review of Immunology. 26 (36), 359-381 (2018).
  25. Palm, N. W., et al. Immunoglobulin a coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 158 (5), 1000-1010 (2014).
  26. Asquith, M., et al. Perturbed mucosal immunity and dysbiosis accompany clinical disease in a rat model of spondyloarthritis. Arthritis Rheumatology. 68 (9), 2151-2162 (2016).
  27. Fransen, F., et al. BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity. Immunity. 43 (3), 527-540 (2015).
  28. Bunker, J. J., et al. Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. Immunity. 43 (3), 541-553 (2015).
  29. Kau, A. L., et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. Science Translational Medicine. 7 (276), 224 (2015).
  30. Serri, A., Mahboubi, A., Zarghi, A., Moghimi, H. R. PAMAM-dendrimer Enhanced Antibacterial Effect of Vancomycin Hydrochloride Against Gram-Negative Bacteria. Journal of Pharmaceutical Sciences. 22 (1), 10-21 (2018).
  31. Boynton, F. D. D., Ericsson, A. C., Uchihashi, M., Dunbar, M. L., Wilkinson, J. E. Doxycycline induces dysbiosis in female C57BL/6NCrl mice. BMC Research Notes. 10 (1), 644 (2017).
  32. Le Bastard, Q., et al. Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice. Scientific Reports. 8 (1), 6219 (2018).
  33. Harris, V. C., et al. Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of-Concept Trial. Cell Host Microbe. 24 (2), 197-207 (2018).
  34. Nakamura, S., et al. Antimicrobial susceptibility of Clostridium difficile from different sources. Microbiology and Immunology. 26 (1), 25-30 (1982).
  35. Robertson, S. J., et al. Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models. Cell Reports. 27 (6), 1910-1919 (2019).
  36. Chagwedera, D. N., et al. Nutrient Sensing in CD11c Cells Alters the Gut Microbiota to Regulate Food Intake and Body Mass. Cell Metabolism. 30 (2), 364-373 (2019).
  37. Truax, A. D., et al. The Inhibitory Innate Immune Sensor NLRP12 Maintains a Threshold against Obesity by Regulating Gut Microbiota Homeostasis. Cell Host Microbe. 24 (3), 364-378 (2018).
  38. Li, Y., et al. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5(-/-) mice. Nature Communications. 10, 16 (2019).
  39. Tian, Z., et al. Beneficial Effects of Fecal Microbiota Transplantation on Ulcerative Colitis in Mice. Digestive Diseases and Sciences. 61 (8), 2262-2271 (2016).
  40. Tang, G., Yin, W., Liu, W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis. Diagnostic Microbiology and Infectious Disease. 88 (4), 322-329 (2017).
  41. Satokari, R., Mattila, E., Kainulainen, V., Arkkila, P. E. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection--an observational cohort study. Alimentary Pharmacology and Therapeutics. 41 (1), 46-53 (2015).
  42. Takahashi, M., et al. Faecal freezing preservation period influences colonization ability for faecal microbiota transplantation. Journal of Applied Microbiology. 126 (3), 973-984 (2019).
  43. Wos-Oxley, M. L., et al. Comparative evaluation of establishing a human gut microbial community within rodent models. Gut Microbes. 3 (3), 234-249 (2012).
  44. Le Roy, T., et al. Comparative Evaluation of Microbiota Engraftment Following Fecal Microbiota Transfer in Mice Models: Age, Kinetic and Microbial Status Matter. Frontiers in Microbiology. 9, 3289 (2018).
  45. Wrzosek, L., et al. Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota. Scientific Reports. 8 (1), 6854 (2018).
  46. Staley, C., et al. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. Microbiome. 5 (1), 87 (2017).
  47. Cao, H., et al. Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine. Scientific Reports. 7 (1), 10322 (2017).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Fecal Microbiota TransplantationGut MicrobiotaIgA coated BacteriaIntestinal BacteriaFMT ProtocolBacterial DepletionReal time PCR16S Ribosomal RNA SequencingFlow CytometryBiological FunctionRecipient Mice

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved